Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Published:2019-04-16 Issue:1 Volume:8 Page:
ISSN:2162-3619
Container-title:Experimental Hematology & Oncology
language:en
Short-container-title:Exp Hematol Oncol

Author:

Jilg Stefanie^ORCID,Hauch Richard T.,Kauschinger Johanna,Buschhorn Lars,Odinius Timo O.,Dill Veronika,Müller-Thomas Catharina,Herold Tobias,Prodinger Peter M.,Schmidt Burkhard,Hempel Dirk,Bassermann Florian,Peschel Christian,Götze Katharina S.,Höckendorf Ulrike,Haferlach Torsten,Jost Philipp J.

Funder

José Carreras Leukämie-Stiftung

Hans-und-Klementia- Langmatz-Stiftung

DGHO

Deutsche Forschungsgemeinschaft

DKTK

Deutsche Krebshilfe

Else Kröner-Fresenius-Stiftung

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s40164-019-0133-1.pdf

Reference15 articles.

1. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–7.

2. Jilg S, Reidel V, Muller-Thomas C, Konig J, Schauwecker J, Hockendorf U, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30(1):112–23.

3. Reidel V, Kauschinger J, Hauch RT, Muller-Thomas C, Nadarajah N, Burgkart R, et al. Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. Oncotarget. 2018;9(25):17270–81.

4. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, et al. BCL-2 family proteins as 5-azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28(8):1657–65.

5. Muller-Tidow C, Schlenk RF. A new option for remission induction in acute myeloid leukaemia. Lancet Oncol. 2018;19(2):156–7.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

2. Dysregulation of BCL-2 family proteins in blood neoplasm: therapeutic relevance of antineoplastic agent venetoclax;Exploration of Medicine;2024-05-10

3. Hematopoietic cell transplantation (HCT) in MDS patients of older age;Leukemia & Lymphoma;2024-02-05

4. Modulation of Autophagy and Apoptosis in Leukemia;Reference Module in Biomedical Sciences;2024

5. Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia;Leukemia Research;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3